Byoung Chul Cho , Grace K. Dy , Tae Min Kim , Debashis Sarker , Omid Hamid , Stephen K. Williamson , Sang-We Kim , Hatim Husain , Fang Fang , Shuquan Chen , Jayakumar Mani , Vladimir Jankovic , Anne Paccaly , Sheila Masinde , Israel Lowy , Laura Brennan , Mark Salvati , Matthew Fury , Karl Lewis
{"title":"PPD01.86 Fianlimab(一种人类淋巴细胞活化基因-3 (LAG-3)单克隆抗体)与 Cemiplimab 联合治疗晚期 NSCLC 的 1 期研究","authors":"Byoung Chul Cho , Grace K. Dy , Tae Min Kim , Debashis Sarker , Omid Hamid , Stephen K. Williamson , Sang-We Kim , Hatim Husain , Fang Fang , Shuquan Chen , Jayakumar Mani , Vladimir Jankovic , Anne Paccaly , Sheila Masinde , Israel Lowy , Laura Brennan , Mark Salvati , Matthew Fury , Karl Lewis","doi":"10.1016/j.jtho.2024.05.159","DOIUrl":null,"url":null,"abstract":"","PeriodicalId":17515,"journal":{"name":"Journal of Thoracic Oncology","volume":null,"pages":null},"PeriodicalIF":21.0000,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"PPD01.86 Phase 1 Study of Fianlimab, a Human Lymphocyte Activation Gene-3 (LAG-3) Monoclonal Antibody, in Combination With Cemiplimab in Advanced NSCLC\",\"authors\":\"Byoung Chul Cho , Grace K. Dy , Tae Min Kim , Debashis Sarker , Omid Hamid , Stephen K. Williamson , Sang-We Kim , Hatim Husain , Fang Fang , Shuquan Chen , Jayakumar Mani , Vladimir Jankovic , Anne Paccaly , Sheila Masinde , Israel Lowy , Laura Brennan , Mark Salvati , Matthew Fury , Karl Lewis\",\"doi\":\"10.1016/j.jtho.2024.05.159\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"\",\"PeriodicalId\":17515,\"journal\":{\"name\":\"Journal of Thoracic Oncology\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":21.0000,\"publicationDate\":\"2024-07-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of Thoracic Oncology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S1556086424003642\",\"RegionNum\":1,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"ONCOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Thoracic Oncology","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1556086424003642","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ONCOLOGY","Score":null,"Total":0}
PPD01.86 Phase 1 Study of Fianlimab, a Human Lymphocyte Activation Gene-3 (LAG-3) Monoclonal Antibody, in Combination With Cemiplimab in Advanced NSCLC
期刊介绍:
Journal of Thoracic Oncology (JTO), the official journal of the International Association for the Study of Lung Cancer,is the primary educational and informational publication for topics relevant to the prevention, detection, diagnosis, and treatment of all thoracic malignancies.The readship includes epidemiologists, medical oncologists, radiation oncologists, thoracic surgeons, pulmonologists, radiologists, pathologists, nuclear medicine physicians, and research scientists with a special interest in thoracic oncology.